Cargando…

Association of Treatment Intensity and Adherence to Lipid-Lowering Therapy with Major Adverse Cardiovascular Events Among Post-MI Patients in Germany

INTRODUCTION: Patients with a history of myocardial infarction (MI) are at very high risk of subsequent cardiovascular events. This study evaluated the association of treatment intensity and adherence to lipid-lowering therapies (LLT) with major adverse cardiovascular events (MACE) among post-MI pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahrens, Ingo, Khachatryan, Artak, Monga, Bondo, Dornstauder, Eugen, Sidelnikov, Eduard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107155/ https://www.ncbi.nlm.nih.gov/pubmed/33830461 http://dx.doi.org/10.1007/s12325-021-01697-8

Ejemplares similares

Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy
por: Sciattella, Paolo, et al.
Publicado: (2021)

Intensity of and Adherence to Lipid‐Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease
por: Mazhar, Faizan, et al.
Publicado: (2022)

Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C
por: Katzmann, Julius L., et al.
Publicado: (2020)

Longitudinal evaluation of treatment patterns, risk factors and outcomes in patients with cardiovascular disease treated with lipid-lowering therapy in the UK
por: Danese, Mark, et al.
Publicado: (2022)

Adherence to Guideline‐Recommended Therapy Is Associated With Decreased Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients With Peripheral Arterial Disease
por: Armstrong, Ehrin J., et al.
Publicado: (2014)

Adherence To Lipid-Lowering Therapy In Patients With Coronary Heart Disease From The State Of Saxony-Anhalt, Germany
por: Waßmuth, Stephan, et al.
Publicado: (2019)

Adherence to lipid-lowering treatment: the patient perspective
por: Casula, Manuela, et al.
Publicado: (2012)

Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Antimicrobial Postexposure Prophylaxis for Anthrax: Adverse Events and Adherence
por: Shepard, Colin W., et al.
Publicado: (2002)

Effects of intensive lipid lowering compared with moderate-intensity lipid lowering on coronary atherosclerotic plaque phenotype and major adverse cardiovascular events in adults with low to intermediate 10-year ASCVD risk (ILLUMINATION study): protocol for a multicentre, open-label, blinded-endpoint, randomised controlled trial
por: Zheng, Jianan, et al.
Publicado: (2023)

Association Between Medication Adherence and 1‐Year Major Cardiovascular Adverse Events After Acute Myocardial Infarction in China
por: Shang, Pu, et al.
Publicado: (2019)

Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels
por: Nelson, Adam J., et al.
Publicado: (2022)

Lipid profiles and risk of major adverse cardiovascular events in CKD and diabetes: A nationwide population-based study
por: Lee, Yeonhee, et al.
Publicado: (2020)

Effectiveness of lipid-lowering therapy on mortality and major adverse cardiovascular event outcomes in patients undergoing percutaneous coronary intervention: a network meta-analysis of randomised controlled trials
por: Deng, Chang-Jiang, et al.
Publicado: (2023)

Xerosis and pruritus as major EGFRI-associated adverse events
por: Clabbers, Julia M. K., et al.
Publicado: (2015)

Association Between Wearable Device–Based Measures of Physical Frailty and Major Adverse Events Following Lower Extremity Revascularization
por: Najafi, Bijan, et al.
Publicado: (2020)

Is tadalafil associated with decreased risk of major adverse cardiac events or venous thromboembolism in men with lower urinary tract symptoms?
por: Goberdhan, Sankalp, et al.
Publicado: (2022)

Novel Insight Into Long-Term Risk of Major Adverse Cardiovascular and Cerebrovascular Events Following Lower Extremity Arteriosclerosis Obliterans
por: Sun, Ji, et al.
Publicado: (2022)

Alive and kicking: suicide rates and major soccer events in Austria, Germany and Switzerland
por: Pichler, Eva-Maria, et al.
Publicado: (2023)

Gut‐Derived Serum Lipopolysaccharide is Associated With Enhanced Risk of Major Adverse Cardiovascular Events in Atrial Fibrillation: Effect of Adherence to Mediterranean Diet
por: Pastori, Daniele, et al.
Publicado: (2017)

Six-month adherence to Statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes
por: Xie, Gaoqiang, et al.
Publicado: (2017)

Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany
por: Link, Hartmut, et al.
Publicado: (2019)

Dynamic changes of monocytes subsets predict major adverse cardiovascular events and left ventricular function after STEMI
por: Boidin, Maxime, et al.
Publicado: (2023)

Urine Klotho Is Lower in Critically Ill Patients With Versus Without Acute Kidney Injury and Associates With Major Adverse Kidney Events
por: Neyra, Javier A., et al.
Publicado: (2019)

Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe
por: Rea, Federico, et al.
Publicado: (2021)

Sarcoidosis: comprehensive CMR evaluation and major adverse cardiac events
por: Higgins, Angela Y, et al.
Publicado: (2016)

Low Prevalance of Major Events Adverse to Exercise Stress Echocardiography
por: Andrade, Stephanie Macedo, et al.
Publicado: (2016)

Risk of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis
por: Mal, Kheraj, et al.
Publicado: (2020)

Prediabetes as a risk factor for major adverse cardiovascular events
por: Mando, Ramy, et al.
Publicado: (2021)

Association of Prior Intracerebral Hemorrhage With Major Adverse Cardiovascular Events
por: Gaist, David, et al.
Publicado: (2022)

Comparison of HEAR and HEART Scores for Major Adverse Cardiovascular Events
por: Uyan, Umut
Publicado: (2023)

Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment
por: Shin, Hong-Joon, et al.
Publicado: (2023)

Associations of Modified Healthy Aging Index With Major Adverse Cardiac Events, Major Coronary Events, and Ischemic Heart Disease
por: Huang, Ninghao, et al.
Publicado: (2023)

Adherence to lipid-lowering guidelines for secondary prevention and potential reduction in CVD events in Swedish primary care: a cross-sectional study
por: Ödesjö, Helena, et al.
Publicado: (2020)

Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events
por: Teimouri, Arezou, et al.
Publicado: (2022)

Lower Plasma Elabela Levels in Hypertensive Patients With Heart Failure Predict the Occurrence of Major Adverse Cardiac Events: A Preliminary Study
por: Ma, Zheng, et al.
Publicado: (2021)

Adverse events in spine surgery: a prospective analysis at a large tertiary center in Germany
por: Lenga, Pavlina, et al.
Publicado: (2023)

Utilization and adherence to guideline-recommended lipid-lowering therapy at an academic medical center
por: Alburikan, Khalid A., et al.
Publicado: (2017)

Impact of cardiac surgery associated acute kidney injury on 1-year major adverse kidney events
por: Molina Andújar, Alícia, et al.
Publicado: (2023)

Impact of heart failure severity and major bleeding events after percutaneous coronary intervention on subsequent major adverse cardiac events
por: Ikebe, So, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1i6m4o90lhv0gpedrvhddhope7